782 Results
Sort By:
Published on December 27, 2023
Needle biopsy is indispensable to the diagnosis, typing, and targeted treatment of breast cancer. A new study, however, indicates that the testing itself triggers a series of cell-level changes that promote the spread of the disease months later. The results are the first of their kind to suggest a mechanism…
Published on December 21, 2023
Researchers at Stanford University have identified a protein, known as ENPP1 that can act as an on/off switch controlling breast cancer cell’s ability to metastasize and resist immunotherapy. Despite the strides made in cancer immunotherapies, a significant hurdle remains: more than 80 percent of advanced breast cancers resist these promising…
Published on December 20, 2023
Researchers observed that cells that are present in cancerous brain cells but not in normal brain tissue—known as cancer-associated fibroblasts (CAFs)—secrete a protein that stimulates breast cancer cells in the brain to migrate and invade more widely. The excreted protein, fucosylated poliovirus receptor (PVF), was shown in mouse models to…
Published on December 13, 2023
Researchers from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard have shown that fusion RNAs are more common than previously thought in people with metastatic breast cancer and could potentially be targeted with drugs that are already available. “The implication of our findings is that fusion…
Published on December 6, 2023
Patients with node-positive breast cancer that becomes node-negative after neoadjuvant chemotherapy can omit regional nodal irradiation (RNI) without increasing their risk for recurrence, suggests data presented at the 2023 San Antonio Breast Cancer Symposium. The de-escalation of treatment could spare a large proportion of patients the side effects associated with…
Published on December 6, 2023
A simple hormone blood test can identify postmenopausal women who will benefit from preventive breast cancer therapy, shows research led by Queen Mary University of London. Post-menopausal women with a medium-higher estradiol-sex hormone binding globulin (SHBG) ratio were shown to have increased cancer risk compared to other postmenopausal women. However,…
Published on November 29, 2023
Precision oncology genomic testing company Personalis announced Tuesday that it is partnering with AI-driven precision medicine company Tempus to co-commercialize its molecular residual disease (MRD) test in lung and breast cancer. The test, NeXT Personal Dx is Personalis’ tumor informed whole-genome liquid biopsy laboratory developed test (LDT) the company launched…
Published on November 27, 2023
A groundbreaking study conducted at Northwestern Medicine suggests that an artificial intelligence (AI) tool could spare breast cancer patients unnecessary chemotherapy treatments by more accurately predicting patient outcomes. The research, published today in Nature Medicine, shows that the AI tool outperformed the analysis of disease by expert pathologists. While current…
Published on November 22, 2023
Scientists at Stanford University have uncovered a novel physical mechanism that breast cancer cells use to break out and become invasive. They observed that in addition to established chemical methods of degrading the basement membrane, cancer cells work as a group to physically deform and tear through the basement membrane…
Published on November 8, 2023
Researchers at the Centre for Genomic Regulation and Vall d’Hebron Institute of Oncology, both in Barcelona, Spain, indicate that simultaneously inhibiting two specific proteins could slow the growth of triple-negative breast cancer (TNBC). The study, which appears in the journal EMBO Molecular Medicine, could have siginficant implications for this hard…
Published on November 1, 2023
A team of researchers at Baylor College of Medicine—and collaborating institutions—have discovered in animal model testing that Zotatifin a drug targeting the elF4A protein suppressed tumor cell proliferation and remodeled the tumor immune microenvironment and could be a key to treating triple-negative breast cancer (TNBC). The findings, reported in The…
Published on November 1, 2023
New research reveals that an important priming phase makes breast cancer cells previously exposed to sublethal drug concentrations refractory to higher doses. Using spatiotemporal modeling, a University of Ottawa (uOttawa) team found, specifically, that chemotherapy-resistant breast cancer cells throughout the cellular concentration gradient have higher expression of the solute carriers…
Published on October 30, 2023
New research led by Penn State researchers has shown, for the first time, the mechanics of how breast cancer cells invade healthy tissues and lead to metastatic disease. The findings, published in the journal Advanced Science, demonstrates that the motor protein dynein was critical in driving the movement of cancer…
Published on October 18, 2023
The good news is a vast majority of adults—93%—recognized that the presence of a lump is a symptom of breast cancer. The bad news: fewer than half of those surveyed by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) recognize…
Published on October 4, 2023
A team of investigators at Vanderbilt-Ingram Cancer Center, reporting in Cancer Discovery, has discovered a druggable target on natural killer cells that could create a therapeutic response in patients with immunotherapy-resistant triple-negative breast cancer. While immunotherapy has shown promise across a range of cancers and tumor types, only about 15%…